These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 25836940)

  • 1. Future directions and targeted therapies in bladder cancer.
    Sonpavde G; Jones BS; Bellmunt J; Choueiri TK; Sternberg CN
    Hematol Oncol Clin North Am; 2015 Apr; 29(2):361-76, x. PubMed ID: 25836940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging drugs for urothelial carcinoma.
    Gartrell BA; Sonpavde G
    Expert Opin Emerg Drugs; 2013 Dec; 18(4):477-94. PubMed ID: 24195728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic and DNA-targeted therapy in urothelial cancer: have we squeezed the lemon enough?
    Balar AV; Milowsky MI
    Cancer; 2015 Jan; 121(2):179-87. PubMed ID: 25091501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy.
    Galsky MD; Krege S; Lin CC; Hahn N; Ecke T; Moshier E; Sonpavde G; Godbold J; Oh WK; Bamias A
    Cancer; 2013 Aug; 119(16):3020-6. PubMed ID: 23720197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting.
    Gallagher DJ; Milowsky MI; Bajorin DF
    Cancer; 2008 Sep; 113(6):1284-93. PubMed ID: 18629841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chemotherapy for urothelial cancer of the bladder--update 2012].
    Niegisch G; Lorch A; Albers P
    Aktuelle Urol; 2012 Dec; 43(6):412-9. PubMed ID: 23196781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current treatment of metastatic bladder cancer and future directions.
    Lei AQ; Cheng L; Pan CX
    Expert Rev Anticancer Ther; 2011 Dec; 11(12):1851-62. PubMed ID: 22117153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line treatment of metastatic disease: cisplatin-ineligible patients.
    Cathomas R; De Santis M; Galsky MD
    Hematol Oncol Clin North Am; 2015 Apr; 29(2):329-40, x. PubMed ID: 25836938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chemotherapy of bladder carcinoma. Current status and trends].
    Block T
    Urologe A; 1994 Nov; 33(6):557-67. PubMed ID: 7817457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy.
    Galsky MD; Moshier E; Krege S; Lin CC; Hahn N; Ecke T; Sonpavde G; Godbold J; Oh WK; Bamias A
    Cancer; 2013 Aug; 119(16):3012-9. PubMed ID: 23720216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.
    Ortmann CA; Mazhar D
    Future Oncol; 2013 Nov; 9(11):1637-51. PubMed ID: 24156324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic therapy for metastatic bladder cancer in 2016 and beyond.
    Collazo-Lorduy A; Galsky MD
    Future Oncol; 2016 May; 12(9):1179-92. PubMed ID: 26922914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy for bladder cancer.
    Sonpavde G; Lerner SP
    Oncology (Williston Park); 2007 Dec; 21(14):1673-81; discussion 1686-8, 1691, 1694. PubMed ID: 18247016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel for the treatment of bladder cancer.
    Albany C; Sonpavde G
    Expert Opin Investig Drugs; 2015; 24(12):1657-64. PubMed ID: 26535615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of patients with muscle-invasive and metastatic bladder cancer.
    Henry NL; MacVicar G; Hussain M
    Oncology (Williston Park); 2005 Sep; 19(10):1333-42; discussion 1342, 1347, 1350 passim. PubMed ID: 16285227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer.
    Necchi A; Mariani L; Giannatempo P; Raggi D; Farè E; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Maffezzini M; Pizzocaro G; De Braud FG; Gianni AM; Salvioni R
    Clin Genitourin Cancer; 2014 Jun; 12(3):203-209.e1. PubMed ID: 24394493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and therapeutic applications of the molecular events in clinical management of urothelial carcinoma of bladder.
    Garg M
    J Exp Ther Oncol; 2014; 10(4):301-16. PubMed ID: 25509986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic chemotherapy for urothelial cancer.
    Sonpavde G; Hutson TE; Berry WR
    Clin Genitourin Cancer; 2006 Jun; 5(1):34-42. PubMed ID: 16859577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular biology and targeted therapies for urothelial carcinoma.
    Seront E; Machiels JP
    Cancer Treat Rev; 2015 Apr; 41(4):341-53. PubMed ID: 25828962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line treatment and prognostic factors of metastatic bladder cancer for platinum-eligible patients.
    Abida W; Bajorin DF; Rosenberg JE
    Hematol Oncol Clin North Am; 2015 Apr; 29(2):319-28, ix-x. PubMed ID: 25836937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.